A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma

E. Copelan, B. Pohlman, L. Rybicki, M. Kalaycio, R. Sobecks, S. Andresen, R. Dean, A. Koo, J. Chan, J. Sweetenham, B. Bolwell

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Some reports have suggested that rituximab administration before PBSC mobilization may adversely affect PBSC yield. We conducted a prospective randomized trial of PBSC mobilization using etoposide and G-CSF with or without rituximab to determine whether its addition would adversely affect CD34+ cell yield in patients with non-Hodgkin's lymphoma. Twenty seven patients were mobilized with etoposide and G-CSF and 28 with etoposide, G-CSF and rituximab. There were no adverse consequences of rituximab on CD34+ cell yield, or hematopoietic recovery or immunoglobulin levels after transplantation.

Original languageEnglish (US)
Pages (from-to)101-105
Number of pages5
JournalBone Marrow Transplantation
Volume43
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'A randomized trial of etoposide and G-CSF with or without rituximab for PBSC mobilization in B-cell non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this